People | Locations | Statistics |
---|---|---|
Naji, M. |
| |
Motta, Antonella |
| |
Aletan, Dirar |
| |
Mohamed, Tarek |
| |
Ertürk, Emre |
| |
Taccardi, Nicola |
| |
Kononenko, Denys |
| |
Petrov, R. H. | Madrid |
|
Alshaaer, Mazen | Brussels |
|
Bih, L. |
| |
Casati, R. |
| |
Muller, Hermance |
| |
Kočí, Jan | Prague |
|
Šuljagić, Marija |
| |
Kalteremidou, Kalliopi-Artemi | Brussels |
|
Azam, Siraj |
| |
Ospanova, Alyiya |
| |
Blanpain, Bart |
| |
Ali, M. A. |
| |
Popa, V. |
| |
Rančić, M. |
| |
Ollier, Nadège |
| |
Azevedo, Nuno Monteiro |
| |
Landes, Michael |
| |
Rignanese, Gian-Marco |
|
Tajbakhsh, Amir
in Cooperation with on an Cooperation-Score of 37%
Topics
Publications (3/3 displayed)
- 2019The Impact of CASP8 rs10931936 and rs1045485 Polymorphisms as well as the Haplotypes on Breast Cancer Riskcitations
- 2016New approaches to use nanoparticles for treatment of colorectal cancer; a brief review
- 2015Association of tumor necrosis factor-α promoter G-308A gene polymorphism with increased triglyceride level of subjects with metabolic syndromecitations
Places of action
Organizations | Location | People |
---|
document
New approaches to use nanoparticles for treatment of colorectal cancer; a brief review
Abstract
<p>Nanoparticles have been at the center of research focus as a new promising material for the treatment of cancer in recent years. Although many chemotherapy drugs for cancer treatment are available, their potential toxicity is the main point of concern. On the other hand, the conventional chemotherapeutic approach has not been found to be very efficient in colorectal cancer (CRC) as the drug molecule does not reach the target site with an effective concentration. A major challenge in cancer therapy is to destroy tumor cells without harming the normal tissue. To overcome this problem scientists are trying to use nanoparticles to directly target cancer cells for a more effective treatment and reduced toxicity. Different nanoparticles such as: liposomes, polymeric nanoparticles, dendrimers, and silica have been developed to carry a variety of anticancer agents including: cytotoxic drugs, chemo modulators, siRNA and antiangiogenic agents. This review discusses various treatments for colon cancer and the potential use of nanoparticles which facilitate targeting of cancer cells. The outlook for new treatment strategies in CRC management is also underlined.</p>